M3 Biotechnology is an innovative therapeutics company that has a novel platform of disease-modifying regenerative small molecules, particularly relevant to neurodegenerative diseases. The lead compound modifies growth-factor systems, where the activation is expected to stop disease progression and even restore lost function. The company’s research has been funded by the Alzheimer’s Drug Discovery Foundation, Washington’s Life Sciences Discovery Fund, W Fund, WRF Capital, Dolby Family Ventures and other private investors.
Where current and emerging therapies are focused primarily on disease symptoms and improving the quality of life of patients suffering from disease, M3 differentiates itself from the competition by addressing the neurodegenerative process, providing a cost-effective solution and feasible delivery mechanism. Our strategy is to leverage our patented and proprietary technologies to develop small molecule modulators with a primary focus on altering the course of Alzheimer’s Disease progression and neuro-deterioration.